Copy to clipboard 
Tecomet and Orchid Orthopedic Solutions have entered into a definitive agreement to merge, bringing together complementary capabilities to increase capacity, expand their reach and support long-term growth for the company. The merger combines two of the largest contract manufacturers in the orthopedic space and will likely have a profound impact on the supply chains of the top OEMs.
Until the transaction closes, Tecomet and Orchid will operate as separate companies. The merger is subject to regulatory approvals and other customary closing conditions and is expected to take several months to finalize.
Tecomet and Orchid are both global leaders in the design, development and manufacture of orthopedic devices across all markets, but have a significant presence in joint replacement due to their expertise in casting and forging.
The two companies offer broad capabilities as total solutions providers with differentiating primary offerings. Additive manufacturing has become a strategic growth area for Orchid, particularly for large joint applications. In 2023, the company partnered with GE Additive to advance its 3D printing capabilities with electron beam melting. Tecomet has long been a leading supplier of co-developed, high-precision instruments, as well as cases and trays.
The merged company also will have a significant presence in the global supply chain. Tecomet currently operates 14 manufacturing locations across the U.S., Europe and Asia, while Orchid supports 10 locations in the U.S., U.K. and Switzerland.
In recent years, orthopedic contract manufacturers have been challenged by large OEM acquisitions and extreme market forces, including the pandemic, product supply fluctuation, inflation and tariffs. During the OMTEC 2025 keynote, Orchid CEO Nate Folkert noted how punishing the market has been for contract manufacturing.
The merger is intended to increase the combined company’s competitiveness and strengthen its ability to reliably manufacture and deliver high-quality, cost-effective products to its customers, said Tecomet President and CEO Andreas S. Weller. “We operate in a highly competitive space, and we strive to provide the highest quality products and services to our customers,” he told BONEZONE. “What matters most does not change — our commitment to quality and reliability. The work we do supports life-improving outcomes.”
Leadership from Tecomet and Orchid believe the merger will enhance the company’s portfolio by providing a broader, more resilient manufacturing business and increasing its ability to invest in advanced manufacturing technologies, automation and capacity — all capabilities they said their OEM customers are demanding.
“Strategically, this is a strong fit,” Folkert said. “By combining our manufacturing capabilities, technical expertise and global footprints, we’re creating a stronger, more competitive organization. Just as importantly, this combination is about long-term stability – building a company that is well equipped to grow, invest and create opportunity for our people.”
Tecomet is owned by Charlesbank Capital Partners and Orchid is owned by Nordic Capital. Both private equity firms will have an ownership stake in the merged company.
Weller said that decisions about the leadership structure of the combined organization will be made during the forthcoming integration planning process. The goal is to create an executive team that will effectively guide the company.
